Validation of an internationally derived patient severity phenotype to support COVID-19 analytics from electronic health record data


1Laboratory of Computer Science, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA, 2Department of Biomedical Informatics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA, 3IAM Unit, Public Health Department, Bordeaux University Hospital, Bordeaux, France, 4Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA, 5Research Information Science and Computing, Mass General Brigham, Boston, Massachusetts, USA, 6Institute of Medical Biometry and Statistics, Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 7Department of Anesthesiology, Critical Care, and Pain Medicine, Children's Hospital, Boston, Massachusetts, USA, 8Computational Health Informatics Program, Boston Children's Hospital, Boston, Massachusetts, USA, 9Laboratory of Informatics and Systems Engineering for Clinical Research, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy, 10Section of Nephrology, Department of Pediatrics, Brenner Children's Hospital, Wake Forest School of Medicine, Winston Salem, North Carolina, USA, 11Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA, 12Department of Computer Science and Bioinformatics, University of Michigan, Ann Arbor, Michigan, USA, 13Department of Biomedical Informatics-WisDM, National University Health System, Singapore, 14Department of Biostatistics, Epidemiology, and Informatics, Institute for Biomedical Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA, 15Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA, 16Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, Michigan, USA, 17Department of Electrical, Computer and Biomedical Engineering, University of Pavia, Italy, 18Division of Critical Care, National University Health System, Singapore, 19Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA, 20Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy, 21Division of Infectious Diseases, Department of Medicine II, Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 22National Center for Infectious Diseases, Tan Tock Seng Hospital, Singapore, 23ERIAS-INSEMR U1219 BPH, Bordeaux University Hospital, Bordeaux, France, 24Data Analytics Center, Penn Medicine, Philadelphia, Pennsylvania, USA, 25Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA, 26Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA, 27Department of Neurology, Massachusetts General Hos-
ABSTRACT

Objective: The Consortium for Clinical Characterization of COVID-19 by EHR (4CE) is an international collaboration addressing coronavirus disease 2019 (COVID-19) with federated analyses of electronic health record (EHR) data. We sought to develop and validate a computable phenotype for COVID-19 severity.

Materials and Methods: Twelve 4CE sites participated. First, we developed an EHR-based severity phenotype consisting of 6 code classes, and we validated it on patient hospitalization data from the 12 4CE clinical sites against the outcomes of intensive care unit (ICU) admission and/or death. We also piloted an alternative machine learning approach and compared selected predictors of severity with the 4CE phenotype at 1 site.

Results: The full 4CE severity phenotype had pooled sensitivity of 0.73 and specificity 0.83 for the combined outcome of ICU admission and/or death. The sensitivity of individual code categories for acuity had high variability—up to 0.65 across sites. At one pilot site, the expert-derived phenotype had mean area under the curve of 0.903 (95% confidence interval, 0.886-0.921), compared with an area under the curve of 0.956 (95% confidence interval, 0.952-0.959) for the machine learning approach. Billing codes were poor proxies of ICU admission, with as low as 49% precision and recall compared with chart review.

Discussion: We developed a severity phenotype using 6 code classes that proved resilient to coding variability across international institutions. In contrast, machine learning approaches may overfit hospital-specific orders. Manual chart review revealed discrepancies even in the gold-standard outcomes, possibly owing to heterogeneous pandemic conditions.

Conclusions: We developed an EHR-based severity phenotype for COVID-19 in hospitalized patients and validated it at 12 international sites.

Key words: novel coronavirus, disease severity, computable phenotype, medical informatics, data networking, data interoperability

INTRODUCTION

Background and significance

The coronavirus disease 2019 (COVID-19) pandemic has stretched healthcare systems around the world to capacity. The need for actionable and reliable data has highlighted the value of the electronic health record (EHR). In particular, practice patterns and patient outcomes recorded in the EHR can be rapidly aggregated and analyzed to promote learning, discovery, and clinical feedback. Despite large international investments to build such research networks, progress has been slow. COVID-19 has challenged our informatics infrastructures and highlighted continued weaknesses.

The Consortium for Clinical Characterization of COVID-19 by EHR (4CE) is a recently convened volunteer consortium of over 340 international hospitals that are leveraging EHR data and clinical expertise to develop robust informatics-driven investigations into COVID-19. The approach relies on shared analytics scripts supporting 2 common research analytics formats in which analysis is local and aggregation is central. By leveraging investments in standard analytic models while respecting data governance and patient privacy, we completed the initial phase of the study within 2 months of the pandemic’s beginning, characterizing COVID-19 comorbidities and laboratory test values from 96 hospitals worldwide.

To understand patient disease courses and investigate outcomes using EHR data, reliable and robust measures of disease severity are critical. Intuitively, outcomes such as intensive care unit (ICU) admission and in-hospital death seemed to be good correlates of severity. Early work in 4CE attempted to use these outcomes as severity measures, but it became apparent that these data are not reliably available in all environments. Therefore, 4CE sought to develop a reasonable proxy measure of worse outcomes in hospitalized patients with COVID-19 based on widely available EHR data such as medication, diagnosis, and lab codes. This combination of codes is essentially a computable phenotype, which is commonly used in medical informatics to detect the presence of a disease state through proxy measures when no single validated data element for a disease exists or when individual diagnosis codes are mediocre predictors of actual disease presence.

The most common method for defining a computable phenotype is through clinical and informatics expertise, wherein terms are specified that correlate clinical experience with the phenotype. However, a phenotype can make sense clinically yet have poor performance due to coding anomalies and variation between sites. Alternatively, it is possible to define phenotypes using a data-driven approach that uses statistical algorithms to find predictors of the desired outcomes directly from the data. These can also exhibit generalization problems due to overfitting. Thus, an important next step for either approach is to validate the phenotype, which can be done by comparing the concordance between the derived phenotype and the desired outcome—for which it is a proxy—at multiple sites. Although a variety of methods for defining an outcome are possible, the most reliable method of validating a computable phenotype is to perform chart review, which is considered the gold standard of truth about the patient. For example, identification of ICU admissions is not always accurate, especially in a pandemic, in which formal protocols are not always followed. In hospitals where hallways were converted into ad hoc ICUs to support the surge of sick patients,
standardized EHR data elements such as “transfer to ICU” would not be properly recorded. Manual chart review (and perhaps natural language processing in the near future) would be the only method to discover a patient’s ICU status.

Existing severity measures
There has been heightened interest in disease severity measures since the outbreak of COVID-19. We performed a review of 26 early COVID-19 studies. Five used ICU admission as the severity measure, 1 used American Thoracic Society criteria for severity of community-acquired pneumonia, and the rest used the World Health Organization (WHO) definition. Other severity measures have been suggested; however, they are not widely used or well validated.

The WHO broadly defines “severe” disease as fever or suspected respiratory infection, plus 1 of the following: respiratory rate > 30 breaths/min, severe respiratory distress, or arterial oxygen saturation measured by pulse oximeter ≤ 93% while breathing room air. The WHO definition includes patients admitted to the hospital with pneumonia who can be managed on medical wards and are not critically ill. The best evidence suggests that about 85% of such patients will never progress to critical illness such as acute respiratory distress syndrome (ARDS). ICU admission cannot be used as a severity measure in 4CE because many sites do not have these data available in their EHRs. 4CE is only collecting common EHR data classes (demographics, diagnoses, medications, labs, and International Classification of Diseases [ICD] procedure codes), and thus a 4CE severity measure must include only these classes. The WHO definition has the same issue and is also very inclusive. It is most accurately a proxy for hospital admission (moderate disease), rather than a difficult hospital course (severe disease). As such, the WHO definition is too sensitive for 4CE’s goal of identifying patients with severe disease.

Objective
We set out to develop an EHR-driven severity phenotype as a proxy for worse clinical course in hospitalized patients with COVID-19 and validate it against the outcomes ICU admission and/or death in a subset of the global 4CE consortium. Because outcome data had uncertain accuracy, we performed a focused chart review to better understand validation performance. Finally, we compared a data-driven algorithm at 1 site to the expert-derived 4CE phenotype to understand the strengths and weaknesses of the 2 approaches.

MATERIALS AND METHODS
Defining severity
First, we developed a 4CE severity phenotype that is both clinically reasonable and possible to identify across our diverse sites. To do this, we needed to limit severity to the EHR data classes that 4CE is collecting: demographics, diagnoses, medications, labs, and ICD procedure codes. We did not use outcomes (eg, ICU admission), symptoms (eg, wheezing), or vital signs (eg, respiratory rate), as these are not widely or reliably available in EHRs.

We used the WHO severity definition as a starting point and 2 authors (G.M.W. and G.A.B.) identified a much more specific diagnosis group: patients who required invasive mechanical ventilation for acute respiratory failure or vasoactive medication infusions for shock.

We created a value set of EHR data elements that suggest these disease states, based on commonly available data classes:

- **Lab test:** partial pressure of carbon dioxide or partial pressure of oxygen
- **Medication:** sedatives/anesthetics or treatment for shock
- **Diagnosis:** ARDS, ventilator-associated pneumonia
- **Procedure:** endotracheal tube insertion or invasive mechanical ventilation

These data elements correlate with many individual standard codes. To identify standard codes, we cross-referenced the i2b2 ontology in the ACT (Accrual to Clinical Trials) network. This is a comprehensive terminology dictionary of 2.5 million codes found in many EHRs, with individual codes arranged hierarchically in folders describing the above concepts. The result was a list of ~100 codes in the ICD-9 and ICD-10, LOINC (Logical Observation Identifiers Names and Codes), and RxNorm formats, which are international standards used for research. These are listed in Supplementary Table A1 and on the Github sites for 4CE data extraction and the ACT COVID ontology.

Local sites expanded these standard codes to match their local codes. Often, this was assisted with previous mappings from i2b2 where local items were a child folder of the standard code. When mappings were not straightforward, the terms that most closely matched the definition were used, maximizing semantic equivalence across sites. For example, some U.S. sites had both Current Procedural Terminology (CPT) and ICD procedure codes; the CPT codes were not added when ICD was available. In contrast, because some European sites do not use the U.S. Clinical Modifications of ICD-10, other coding systems like Operation and Procedure Classification codes were added to identify invasive mechanical ventilation.

Because the presence of any of these codes suggest severe disease, patients were assigned the severity phenotype if any code in the value set was generated during the hospital course. This makes the algorithm robust to practice variation—if one site does not include, for example, medication codes, then the severity phenotype can still be assigned through other code categories. Note that for laboratory tests, the phenotype uses the existence of these codes and not the associated value, because performing the test (eg, partial pressure of oxygen) suggests disease severity. Similarly, medication administration, regardless of the dose, indicates severe illness.

Network-wide analysis: 4CE severity validation
To validate the 4CE severity phenotype (and discover whether it actually works in practice), a subset of 12 sites with the necessary data identified patients who were admitted to the ICU and/or who died. Although not a perfect equivalence to severe disease or hospital course, ICU admission and death are objective measures that can be gleaned from patient data. We defined 3 options for confirming ICU admission, in order from most to least accurate:

1. **Chart review.** This is considered the gold standard for identifying outcomes like ICU admission and could have been particularly useful in crisis situations like the COVID-19 pandemic. Nonetheless, chart review is time-consuming and laborious, so this option was impractical without substantial human resources.

2. **Local hospital data.** Hospital systems have idiosyncratic methods of determining ICU status, but they tend to be fairly accurate because they are used to determine admission, discharge, and transfer status and to manage hospital bed allocation. However, not all sites had access to local hospital data, and expertise was...
required to incorporate this information into a data warehouse. Such limitations underscored the rationale for development of the severity phenotype.

3. Specific ICU Current Procedural Terminology (CPT) Procedure Codes. In the United States, healthcare providers and hospitals use CPT codes to bill for provided critical care services. CPT codes for billing time spent providing critical care (99291, 99292) provide a third option for defining ICU admission. These CPT codes were not used to define the severity phenotype.

Each site computed a set of 2 × 2 tables comparing the 4CE severity phenotype with 3 outcomes (death only, ICU only, and ICU or death) (Supplementary Table A2) for all patients in the 4CE cohort. The 4CE cohort included all hospitalized patients with a positive test for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) from 7 days before to 14 days after the hospitalization. Sites calculated sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and F1 score from these tables. We used a fixed-effects meta-analysis model to estimate pooled scores over all sites. Sites then calculated the performance of individual code classes by computing the sensitivity for the same set of 3 outcomes. This analysis gave further insight into the components of the phenotype’s performance at each site. Sensitivity would be highest for the full phenotype, as the trait is assigned when any code in the 4CE severity value set is present. Additionally, each site reported its approach for confirming ICU admission, total number of ICU beds (to give a sense of site capacity), and any variation from the standard 4CE severity definition or cohort definition. Sites performed these analyses between August 5, 2020, and September 18, 2020, reflecting cases that were recorded from March to August 2020.

To understand the practical differences between methods of defining ICU admission, we performed a limited analysis at 2 sites. We used a set of chart-reviewed ICU admission data among 866 confirmed COVID-19 patients from Massachusetts General Hospital (MGH) between March 8 and June 3, 2020. Extensive manual chart reviews were completed by trained reviewers, including physicians, pharmacists, research nurses, and clinical research coordinators. University of Freiburg Medical Center in Germany (UKFR) provided a set of ICU admission flags obtained from manual chart review of 168 patients in their 4CE COVID-19 cohort that were directly related to their COVID-19 hospitalization. We compared coded ICU admissions to the chart-reviewed data at MGH and UKFR for patients in the 4CE cohort. These overlapping data sets allowed us to compare the 2 definitions of ICU admission with the 4CE severity phenotype. We also compared the performance of the chart-reviewed definition to CPT code-based ICU admission (99291 and 99292) using MGH data.

Data-driven pilot analysis
It is possible to define a phenotype using a data-driven (rather than expert-driven) approach. To better understand the differences between a data-driven vs expert-driven severity phenotype, we undertook a machine learning approach at a single site, Mass General Brigham, using an existing computable phenotyping pipeline.

First, we evaluated the classification performance of the 4CE severity phenotype. Second, we performed automated computable phenotyping using the minimize sparsity maximize relevance (MSMR) dimensionality reduction algorithm to select codes from among all possible data elements. In both approaches, we applied generalized linear models (GLMs) with a logit link, binomial distribution, and component-wise functional gradient boosting to develop the computational models. We used the 4CE cohort with ICU admission and/or death as the target for prediction. We trained and tested the models using an 80–20 train-test split, which we iterated 9 times to capture potential variability in performance metrics due to sampling. Model tuning was performed via 5-fold cross-validation. To evaluate the 2 computable phenotyping models, we calculated the area under the receiver operating characteristic curve (AUROC) on the held-out test sets.

RESULTS
4CE severity analysis
Twelve sites participated in this analysis. The site names, locations, number of hospital beds, number of ICU beds, (not reflecting surge capacity), and total 4CE cohort size (rounded to the nearest 10) are shown in Table 1. We also included the data source used for ICU admission and whether the site’s code mapping included any significant additions to the severity value set. (For example, European sites do not use the U.S. ICD-10-CM, so additional standard codes were needed.) In further results, site names were replaced by a randomly assigned region identifier (either USAx for sites in the United States or GLOBALx for others).

The demographic characteristics of the cohorts (all patients vs all patients with the severity phenotype) across the 12 sites are shown in Table 2.

Sites reported the sensitivity, specificity, PPV, and NPV of the 4CE severity phenotype for the outcome of ICU admission and/or death. The pooled F score over 12 sites was estimated as 0.72 (95% confidence interval [CI], 0.63-0.80) using a fixed-effect meta-analysis model. The pooled sensitivity was 0.73 (95% CI, 0.64-0.82) with mean 0.73 (range, 0.56). The pooled specificity was 0.83 (95% CI, 0.76-0.91) with mean 0.80 (range, 0.5). The sensitivity, specificity, PPV, NPV, and F-score by site can be seen in Table 3. Sites also computed these measures separately for ICU admission and death. The pooled specificity went down for the individual outcomes (0.79 for ICU, 0.67 for death), but sensitivity was higher (0.77 for ICU, 0.76 for death). The statistics for the individual outcomes can be seen in Supplementary Table A3 in the Appendix.

Sites computed the sensitivity of individual code classes to understand how each contributed to the performance of the overall metric. Code classes demonstrated high variability of sensitivity across sites (Figure 1). For example, the anesthetic medication class had sensitivity ranging from 0.15 to 0.76. Code class sensitivity for the separate outcomes of ICU admission and death can be seen in Supplementary Figures A1 to A3. Figure 2 shows the percentage of all severe patients with a code in each class. Figure 3 shows the overlap of high-level code classes in a Venn diagram.

Comparison of ICU definitions
We computed the precision and recall of code-defined ICU admission using chart review as the reference at MGH and UKFR. At MGH, we found agreement for ICU admission with 97% precision and 83% recall. At UKFR, we measured 78% precision and 83% recall. At MGH, we also compared agreement of CPT-code ICU admission definition to chart-reviewed ICU admission and found a 49% precision and 49% recall.

We also recomputed summary statistics of the performance of our 4CE severity phenotype for the outcome of ICU admission and/or death using the chart-reviewed definition of ICU. At MGH and UKFR, the sensitivity was higher using the chart-reviewed definition.
The differences between UKFR and MGH (lower agreement precision and higher specificity performance at UKFR) are likely due to UKFR identifying only COVID-19–related ICU admissions, while MGH identified all ICU admissions during the COVID-19 hospitalization.

The full sets of summary statistics are reported in Table 4 and Supplementary Table A4.

### DISCUSSION

When using EHR-derived data for research, we often adopt proxies for outcomes, especially if these outcomes are infrequently or poorly recorded in the EHR. Validation of these proxies is essential so that we can understand their strengths and limitations. Furthermore, to perform research on a network and especially at global scale, the outcome proxies must use data types broadly available through most EHRs and also be validated at multiple sites to account for differences in coding patterns. Examining subgroup performance of the codes can further improve our ability to understand cross-site differences.

In this study, our primary aim was to develop and validate an EHR-based severity phenotype for the international 4CE consortium to enable network-wide research on COVID-19 across heteroge-
neous sites. The EHR proxies we used to test for severity included commonly available elements in the EHR: diagnosis codes, laboratory orders, medication orders, and procedure codes. These elements improve our ability to infer the presence of respiratory distress and shock, which presumably are serious enough to lead to ICU admission, if available, and/or death.

This study highlights the frequent presence of coding differences between sites, as demonstrated by the remarkable variation in sensitivity by code class. Moreover, the codes captured for the severity phenotype at each site were very different. For example, some sites had a very high prevalence of mechanical ventilation codes and blood gas orders, whereas others had a low prevalence of these same measures, likely owing to practice variation and code extraction differences. We compensated for this limitation by employing a logical or (disjunction) method that accounts for this issue by assigning the phenotype if any code class is present. If a local practice tends not to use, for example, invasive mechanical ventilation (some sites might have favored noninvasive ventilation) a severe patient could instead be flagged due to, for example, a partial pressure of oxygen test. This also highlights the importance of expert-derived proxies for accurate EHR-based analysis. Clinicians among the 4CE leadership who understood the vagaries of hospital coding helped several sites to improve their data extraction and analysis, thereby enhancing the data quality of the 4CE initiative.

Given that the codes were a proxy for illness severity, the PPVs we obtained in the range of 0.7 to 0.9 and the NPVs in the range of 0.68 to 0.98 are indicative of the model's overall success. At 3 sites, the 4CE severity phenotype was more sensitive than specific. The phenotype captured not only ICU transfer or patient mortality, but also patients without those outcomes. At most sites (n = 9 of 12), the phenotype had higher specificity than sensitivity; it flagged mostly ICU or deceased patients but missed a small number of patients likely admitted to the ICU for monitoring. This study also highlights the challenges in selecting a gold standard for validation. There is no measurable assessment of a patient's actual complexity, so we chose ICU admission or mortality, as they are commonly used and generally accepted gold standards. However, ICU admission is not always clearly defined, especially during the pandemic. We evaluated 3 ways of identifying ICU admission, with accuracy improving from CPT codes to hospital code ICU designation to chart review by clinical experts. Our separate analysis of ICU admission definition suggests that the particular approach to coding ICU admission could impact measured performance. It also validated our prioritization of choices for defining ICU admission: chart review was preferred, fol-

### Table 2. Demographic characteristics of all patients vs all patients with the severity phenotype, across the 12 sites

<table>
<thead>
<tr>
<th>Category</th>
<th>Group</th>
<th>All Patients (N = 10 340)</th>
<th>Severe Phenotype Patients (n = 3800)</th>
<th>Severe (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0-25 y</td>
<td>450 (4)</td>
<td>90 (3)</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>26-49 y</td>
<td>2180 (21)</td>
<td>630 (17)</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>50-69 y</td>
<td>3740 (36)</td>
<td>1580 (42)</td>
<td>42</td>
</tr>
<tr>
<td></td>
<td>70-79 y</td>
<td>1820 (18)</td>
<td>800 (21)</td>
<td>44</td>
</tr>
<tr>
<td></td>
<td>80+ y</td>
<td>2070 (20)</td>
<td>650 (17)</td>
<td>32</td>
</tr>
<tr>
<td>Sex</td>
<td>Female</td>
<td>4930 (47)</td>
<td>1610 (42)</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>5410 (52)</td>
<td>2190 (58)</td>
<td>41</td>
</tr>
<tr>
<td>Race</td>
<td>White</td>
<td>4210 (42)</td>
<td>1520 (41)</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Black</td>
<td>2550 (25)</td>
<td>1000 (27)</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>Other</td>
<td>3360 (33)</td>
<td>1220 (33)</td>
<td>36</td>
</tr>
</tbody>
</table>

Values are n (%), unless otherwise indicated. Numbers are rounded to the nearest 10.

### Table 3. The sensitivity, specificity, PPV, NPV, and F1 score of the 4CE severity phenotype for the outcome ICU admission and/or death at each site in the United States and outside the United States (Global)

<table>
<thead>
<tr>
<th>GLO1</th>
<th>GLO2</th>
<th>USA5</th>
<th>USA8</th>
<th>USA1</th>
<th>USA3</th>
<th>USA6</th>
<th>GLO5</th>
<th>USA4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>0.35</td>
<td>0.74</td>
<td>0.58</td>
<td>0.66</td>
<td>0.76</td>
<td>0.75</td>
<td>0.73</td>
<td>0.83</td>
</tr>
<tr>
<td>Specificity</td>
<td>0.96</td>
<td>0.93</td>
<td>0.86</td>
<td>0.87</td>
<td>0.89</td>
<td>0.89</td>
<td>0.79</td>
<td>0.96</td>
</tr>
<tr>
<td>PPV</td>
<td>0.55</td>
<td>0.90</td>
<td>0.80</td>
<td>0.75</td>
<td>0.82</td>
<td>0.71</td>
<td>0.73</td>
<td>0.74</td>
</tr>
<tr>
<td>NPV</td>
<td>0.92</td>
<td>0.82</td>
<td>0.68</td>
<td>0.82</td>
<td>0.85</td>
<td>0.91</td>
<td>0.79</td>
<td>0.98</td>
</tr>
<tr>
<td>F-Score</td>
<td>0.43</td>
<td>0.81</td>
<td>0.67</td>
<td>0.70</td>
<td>0.79</td>
<td>0.73</td>
<td>0.73</td>
<td>0.78</td>
</tr>
<tr>
<td>F-Score CI</td>
<td>(0.26-0.60)</td>
<td>(0.74-0.88)</td>
<td>(0.65-0.69)</td>
<td>(0.68-0.73)</td>
<td>(0.74-0.83)</td>
<td>(0.55-0.91)</td>
<td>(0.70-0.76)</td>
<td>(0.67-0.90)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>USA7</th>
<th>USA2</th>
<th>GLO3</th>
<th>Meta-Analysis (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>0.91</td>
<td>0.86</td>
<td>0.88</td>
</tr>
<tr>
<td>Specificity</td>
<td>0.50</td>
<td>0.64</td>
<td>0.46</td>
</tr>
<tr>
<td>PPV</td>
<td>0.70</td>
<td>0.70</td>
<td>0.63</td>
</tr>
<tr>
<td>NPV</td>
<td>0.80</td>
<td>0.82</td>
<td>0.79</td>
</tr>
<tr>
<td>F-Score</td>
<td>0.79</td>
<td>0.77</td>
<td>0.73</td>
</tr>
<tr>
<td>CI</td>
<td>(0.75-0.83)</td>
<td>(0.74-0.82)</td>
<td>(0.68-0.78)</td>
</tr>
</tbody>
</table>

Estimates of the pooled scores were computed using a fixed-effect meta-analysis model.

4CE: Consortium for Clinical Characterization of COVID-19 by EHR; CI: confidence interval; ICU: intensive care unit; NPV: negative predictive value; PPV: positive predictive value.
allowed by hospital codes, and then billing data. The gold standard for validation is chart review, and the differences between what is actually recorded in a patient’s chart and what data elements are available in the EHR are not always appreciated. In our analysis, chart review as compared with hospital data had precision of 97% (MGH) and 78% (UKFR) and recall of 83% (MGH) and 85% (UKFR), owing largely to ICU admissions missed in hospital codes. This is probably due to pandemic conditions, in which nontrad-

Figure 1. Sensitivity of code classes to identify intensive care unit (ICU) admission and/or death. ARDS: acute respiratory distress syndrome; PaCO₂: partial pressure of carbon dioxide; PaO₂: partial pressure of oxygen; RX: medication.

Figure 2. Percentage of patients identified by the Consortium for Clinical Characterization of COVID-19 by EHR severity phenotype, broken down by code class. ARDS: acute respiratory distress syndrome; PaCO₂: partial pressure of carbon dioxide; PaO₂: partial pressure of oxygen; RX: medication.
tional spaces were converted into ICUs to support the surge of sick patients. The 4CE severity phenotype performed better overall when using chart review–based ICU admission and was able to correctly identify more severe patients. Sensitivity increased by 0.22 at MGH and 0.11 at UKFR. Change in specificity was mixed, but this was likely influenced by the different ICU admission targets at the 2 sites (all ICU admissions at MGH vs COVID-related ICU admissions at UKFR). Billing codes were significantly less precise, missing many ICU admissions, yielding 49% precision and 49% recall. In the next phase of our work, it will be important to validate our findings with the addition of clinical notes at additional sites.

We explored a machine learning data-driven approach at a single site and compared the results to our expert-derived phenotype. Among the top 10 features identified by the data-driven model, 4 were conceptually similar to the expert-derived phenotype. Three were labs that occurred more frequently in the ICU than on the floor, which reflects ordering pattern biases, rather than clinically meaningful data points.31 The remaining orders were interesting proxies of the ICU (eg, chlorhexidine, an antibacterial agent used for cleaning the skin). These proxies may be less generalizable than expert-curated codes.

LIMITATIONS
Our data-driven computable exploration was only performed at 1 site. In the future, we hope to engage a larger sample of sites in a data-driven analysis, which would allow us to pool together a list of common codes to better discern generalizability. This will become possible as the 4CE network expands its computational infrastructure.

Additionally, the data analysis was conducted at sites during a surge in the COVID-19 pandemic, which could create unanticipated bias in the results.

CONCLUSION
We developed an EHR-based severity phenotype that can be used when longer-term outcomes data are not readily or reliably available. We validated this at 12 international 4CE sites and confirmed

### Table 4. Comparing the performance of the 4CE severity phenotype when using chart-reviewed ICU admission data or hospital codes at MGH and UKFR

<table>
<thead>
<tr>
<th></th>
<th>MGH Hospital</th>
<th>MGH Chart</th>
<th>UKFR Hospital</th>
<th>UKFR Chart</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>0.58</td>
<td>0.80</td>
<td>0.74</td>
<td>0.85</td>
</tr>
<tr>
<td>Specificity</td>
<td>0.86</td>
<td>0.75</td>
<td>0.93</td>
<td>0.96</td>
</tr>
<tr>
<td>PPV</td>
<td>0.80</td>
<td>0.57</td>
<td>0.90</td>
<td>0.93</td>
</tr>
<tr>
<td>NPV</td>
<td>0.68</td>
<td>0.90</td>
<td>0.82</td>
<td>0.91</td>
</tr>
</tbody>
</table>

The hospital column is repeated from Table 2 for clarity.

4CE: Consortium for Clinical Characterization of COVID-19 by EHR; MGH: Massachusetts General Hospital; NPV: negative predictive value; PPV: positive predictive value; UKFR: University of Freiburg Medical Center in Germany.
its good performance, owing largely to its inclusiveness and breadth. We discovered many coding differences in individual EHR elements across sites. Additionally, we explored the comparison of an expert-derived proxy to a data-driven acuity score that maximized performance at individual sites. Finally, we found differences in ICU admission definitions, revealing that chart review captured information that was not reliable in hospital administrative data.

**FUNDING**

This work was supported by: National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke Grant No. R01NS098023; NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development Grant No. K12 HD047349; NIH National Heart, Lung, and Blood Institute Grant Nos. K23-HL148394, L40-HL148910, and U01HL121518; NIH National Center for Advancing Translational Sciences Grant Nos. U01TR002623, UL1-TR001420, UL1-TR001878, UL1-TR002240, UL1-TR001881, UL1-TR00185705, and SUL1-TR001857-05; NIH National Library of Medicine Grant Nos. R01 LM012095 and R01LM013345; NIH National Human Genome Research Institute Grant No. 5R01HG009174-04; and German Federal Ministry of Education and Research Grant No. FKZ 01ZZ1801B.

**ETHICS APPROVAL**

Each institution reported obtaining proper institutional review board approval for data sharing. Certifications of waivers or approval were collected by the consortium. As data were transmitted in aggregate, no patient level data were available from any site.

**SUPPLEMENTARY MATERIAL**

Supplementary Appendix is available at *Journal of the American Medical Informatics Association* online.

**ACKNOWLEDGMENTS**

The authors thank all members of the 4CE Consortium (see list in the Supplementary Appendix) and all the effort and hard work of the local teams at the 12 sites. Thanks also to Brigitta Gough and Margaret Vella for their help in preparing this manuscript for submission, which was itself a massive undertaking.

**CONFLICT OF INTEREST STATEMENT**

RB and AM are shareholders of Biomeris s.r.l. KDM is an advisor to Medal, Inc.
DATA SHARING
All data collected for this study is presented in the manuscript or appendix. The 4CE provides additional visualizations and data for other consortium projects (https://covidclinical.net).

REFERENCES